We have located links that may give you full text access.
CLINICAL TRIAL
COMPARATIVE STUDY
JOURNAL ARTICLE
MULTICENTER STUDY
RESEARCH SUPPORT, NON-U.S. GOV'T
Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. The Clinical Quality Improvement Network (CQIN) Investigators.
Canadian Journal of Cardiology 1998 May
OBJECTIVE: To define contemporary utilization patterns of anticoagulant and antiplatelet therapy for thromboembolic prophylaxis in atrial fibrillation (AF).
DESIGN: Retrospective medical records audit of patients admitted in 1993 and 1994.
SETTING: Twelve Canadian hospitals.
PATIENTS: Three thousand, three hundred and seventy-five consecutive patients with AF; 1570 females and 2005 males. The mean age was 72 years; 1353 patients were younger than 70 years and 2222 were aged 70 years and older.
MEASUREMENTS AND RESULTS: Overall, 1188 (33%) of the 3575 patients received no prophylaxis, 852 (24%) were treated with warfarin alone, 1247 (35%) received acetylsalicylic acid (ASA) alone and 288 (8%) received both drugs. The pattern of medication use did not change appreciably when possible contraindications to warfarin or ASA therapy were considered. Among the 331 AF patients with valvular heart disease and no contraindications to thromboembolic prophylaxis, 65 (20%) received neither treatment, 181 (55%) received warfarin therapy alone, 46 (14%) received ASA alone and 39 (12%) received both. Among the 2199 AF patients with nonvalvular heart disease and no contraindications, 823 (37%) did not receive either therapy, 677 (31%) received ASA alone, 504 (23%) received warfarin alone and 195 (9%) received both. Elderly and female patients were less likely to receive thromboembolic prophylaxis.
CONCLUSIONS: Anticoagulation and antiplatelet prophylaxis in AF appears to be less than optimal. Although concerns about bleeding may be one reason thromboembolic prophylaxis is so unevenly and incompletely applied, it will be important to determine the reasons for this practice and to develop effective strategies in order to enhance the process of care and patient outcomes.
DESIGN: Retrospective medical records audit of patients admitted in 1993 and 1994.
SETTING: Twelve Canadian hospitals.
PATIENTS: Three thousand, three hundred and seventy-five consecutive patients with AF; 1570 females and 2005 males. The mean age was 72 years; 1353 patients were younger than 70 years and 2222 were aged 70 years and older.
MEASUREMENTS AND RESULTS: Overall, 1188 (33%) of the 3575 patients received no prophylaxis, 852 (24%) were treated with warfarin alone, 1247 (35%) received acetylsalicylic acid (ASA) alone and 288 (8%) received both drugs. The pattern of medication use did not change appreciably when possible contraindications to warfarin or ASA therapy were considered. Among the 331 AF patients with valvular heart disease and no contraindications to thromboembolic prophylaxis, 65 (20%) received neither treatment, 181 (55%) received warfarin therapy alone, 46 (14%) received ASA alone and 39 (12%) received both. Among the 2199 AF patients with nonvalvular heart disease and no contraindications, 823 (37%) did not receive either therapy, 677 (31%) received ASA alone, 504 (23%) received warfarin alone and 195 (9%) received both. Elderly and female patients were less likely to receive thromboembolic prophylaxis.
CONCLUSIONS: Anticoagulation and antiplatelet prophylaxis in AF appears to be less than optimal. Although concerns about bleeding may be one reason thromboembolic prophylaxis is so unevenly and incompletely applied, it will be important to determine the reasons for this practice and to develop effective strategies in order to enhance the process of care and patient outcomes.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app